Literature DB >> 7752070

Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism.

Q Jiang1, A Seyed-Mozaffari, A Sebastian, S Archer, J M Bidlack.   

Abstract

Irreversible opioid antagonists, when administered at small doses, require several hours to display their antagonism of antinociception mediated by opioid receptors. However, most opioid affinity ligands only need a few minutes to produce wash-resistant inhibition of opioid binding to brain membranes. Our study investigated whether the irreversible antagonists, beta-funaltrexamine (beta-FNA), 14 alpha, 14'beta-[dithiobis[(2-oxo-2,1-ethanediyl)imino]]-7,8-dihydro-N- (cyclopropylmethyl)normorphine (N-CPM-TAMO), and N-cyclopropylmethyl-5 beta-methyl- beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone (N-CPM-MET-CAMO) had any effect on morphine-induced antinociceptive tolerance before the appearance of their antagonism in the mouse tail-flick assay. All opioids were given by i.c.v. administration. The irreversible antagonists, beta-FNA (20 nmol), N-CPM-TAMO (0.5 nmol) and N-CPM-MET-CAMO (1 nmol) did not produce any antagonism of morphine-induced analgesia until at least 8 hr after administration. Pretreatment with morphine (3 nmol, -140 min) produced acute antinociceptive tolerance as demonstrated by a 45-fold rightward shift of the morphine dose-response curve. When coadministered with morphine, beta-FNA, N-CPM-TAMO and N-CPM-MET-CAMO completely prevented the development of morphine tolerance 140 min after administration in a dose-dependent manner. This preventive effect lasted for up to 420 min, during which time, morphine was given repeatedly up to four times. This antinociception produced by morphine after coadministration with irreversible antagonists was antagonized by naloxone, demonstrating that morphine-induced analgesia was still mediated by opioid receptors. The kappa- and delta-selective opioid antagonists, nor-binaltorphimine and ICI 174,864, respectively, did not block the preventive effect produced by the irreversible antagonists.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7752070

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.

Authors:  M Hiramatsu; K Inoue; A Ambo; Y Sasaki; T Kameyama
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.

Authors:  Gerta Cami-Kobeci; Willma E Polgar; Taline V Khroyan; Lawrence Toll; Stephen M Husbands
Journal:  J Med Chem       Date:  2011-09-07       Impact factor: 7.446

3.  A novel Gbetagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence.

Authors:  Jennifer L Mathews; Alan V Smrcka; Jean M Bidlack
Journal:  J Neurosci       Date:  2008-11-19       Impact factor: 6.167

4.  Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity.

Authors:  Thomas A Munro; Loren M Berry; Ashlee Van't Veer; Cécile Béguin; F Ivy Carroll; Zhiyang Zhao; William A Carlezon; Bruce M Cohen
Journal:  BMC Pharmacol       Date:  2012-05-29

5.  Phenylalanine Stereoisomers of CJ-15,208 and [d-Trp]CJ-15,208 Exhibit Distinctly Different Opioid Activity Profiles.

Authors:  Ariana C Brice-Tutt; Sanjeewa N Senadheera; Michelle L Ganno; Shainnel O Eans; Tanvir Khaliq; Thomas F Murray; Jay P McLaughlin; Jane V Aldrich
Journal:  Molecules       Date:  2020-09-02       Impact factor: 4.411

6.  Bis-Cyclic Guanidine Heterocyclic Peptidomimetics as Opioid Ligands with Mixed μ-, κ- and δ-Opioid Receptor Interactions: A Potential Approach to Novel Analgesics.

Authors:  Jay P McLaughlin; Ramanjaneyulu Rayala; Ashley J Bunnell; Mukund P Tantak; Shainnel O Eans; Khadija Nefzi; Michelle L Ganno; Colette T Dooley; Adel Nefzi
Journal:  Int J Mol Sci       Date:  2022-08-25       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.